Workshop summary

The use of pharmacotherapies for smoking cessation during pregnancy

^a Departments of Medicine, Psychiatry, and Biopharmaceutical Sciences, University of California-San Francisco, San Francisco, California, USA, ^b Department of Pediatrics, University of California-San Francisco, ^c Smoke-Free Families Program, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama, USA, ^d Department of Psychiatry, University of Vermont, Burlington, Vermont, USA, ^e Center for Health Promotion Research and Prevention, University of Texas-Houston Health Science Center, School of Public Health, Houston, Texas, USA, ^f Department of Obstetrics and Gynecology, Mayo Medical School, Rochester, Minnesota, USA, ^g Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA, ^h Research and Evaluation Unit, The Robert Wood Johnson Foundation, Princeton, New Jersey, USA, ⁱ Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA, ^j Center for Research on Mothers and Children, National Institute for Child Health and Human Development, Bethesda, Maryland, USA

Correspondence to: H Pennington Whiteside, Jr, MSPH, Smoke-Free Families National Program Office, University of Alabama at Birmingham, School of Medicine, Department of Obstetrics and Gynecology, 320 CIRC, 1530 3rd Avenue South, Birmingham, AL 35294-0021, USA; hpw@uab.edu

	Introduction

A workshop entitled "The use of pharmacotherapies for smoking cessation during pregnancy", sponsored by the National Institute of Child Health and Human Development (NICHD) and the Robert Wood Johnson Foundation (RWJF), was held in Rockville, Maryland, on 19 May 1999. The goals of the workshop were: (1) to determine the current state of knowledge related to the use of pharmacotherapies for smoking cessation during pregnancy; and (2) to outline a research agenda to determine the effectiveness and safety of these pharmacotherapies. Attending the workshop were many of the academic experts working in this area in the USA and representatives from NICHD, RWJF, the National Cancer Institute (NCI), the National Institute of Drug Abuse (NIDA), the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), the American College of Obstetrics and Gynecology (ACOG), the Society for Research on Nicotine and Tobacco (SRNT), and several pharmaceutical companies.

	Background

In the USA, . . . [Full text of this article]